Milk Exomes LL oral delivery: Scroll to: B. S
Post# of 145746
![](/assets/46931549/no_avatar_available_thumb.jpg)
Scroll to:
B. Source of Milk Vesicles
Scroll to:
Table 8 below provides exemplary anti-inflammatory agents that can be used, either alone or in combination with an anti-infection agent, in treatment of an infection.
Such agents also can be loaded into LNP-MPVs for oral delivery.
Excerpt from that section:
"Minimize a dysregulated inflammatory response and cytokine storm in patients with acute infection CYDY , NIH of Mexico PRO 140 (leronlimab) CCR5 antagonist"
___________
Look @ one of the Authors of the patent, Bhushan Pattni, LinkedIn excerpt under PureTech on this milk exomes patent program, although he left in 2021:
"Discuss, develop and present milestones for the lead products within the company and with its multi-national collaborators and strategic partners (Roche)"
https://www.linkedin.com/in/bhushan-pattni-phd-52733b17
Author Joseph Bolen is @ PureTech.
___________
Does Roche own the drug mentioned by Cytodyn, in Monday's news ? Think that's what someone posted.
1st study I have seen stating Leronlimab can be given orally. Sending patent link to Cytodyn info.
If they are already aware &/or looking into this...then.
Don't want to get to excited, but....wow the potential this would be, even if for only certain situations.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)